Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0010200 (
cough
)
23,843
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
With the availability of a wide selection of antihypertensive drugs acting by different mechanisms, it should be possible to match the requirement of individual patients with the pharmacological and clinical properties of an appropriate agent. Although the concept of stepped-care therapy is now largely outdated, therapy must be initiated with one agent. Diuretics remain a first-choice option in the elderly and in Black patients, as do calcium antagonists. In patients with ischaemic heart disease or enhanced adrenergic drive, beta-blockers are preferred. Calcium antagonists or
ACE
inhibitors are finding increasing use as initial therapy when quality of life is important and metabolic neutrality is required. The choice of antihypertensive agent may be limited by adverse effects, e.g. pedal oedema with nifedipine, constipation with verapamil, and
cough
with
ACE
inhibitors. Certain advantages are evident for both calcium antagonists and
ACE
inhibitors. Calcium antagonists are more likely to be effective first-line therapy than
ACE
inhibitors in Black patients, in those with a high salt intake, in patients with Raynaud's disease, and when angina pectoris is present.
ACE
inhibitors are preferred for use in combination with diuretic agents, and in the presence of congestive heart failure or low salt intake. Combination therapy between these 2 drug classes is finding increasing acceptance because of its many theoretical advantages, and may provide a means of maximising benefit.
...
PMID:Choosing the correct drug for the individual hypertensive patient. 128 79
We describe two patients demonstrating a granulomatous inflammation of bronchial mucosa characterized clinically by a persistent dry
cough
, lack of manifestations of bronchial asthma, normal level of serum IgE and serum
ACE
, inflamed bronchial mucosal appearance consisting of edema, erythema, bleeding and narrowing and recovering without specific treatment. Histopathological findings of the bronchial inflammation of our patients were characterized by noncaseating granuloma formation consisting of epithelioid cells and multinucleated giant cells with infiltration of lymphocytes, plasma cells and eosinophils. The bronchial granulomatous inflammation of our patients was thought to differ from that of diseases which have been known, to our knowledge, as diseases demonstrating a granulomatous inflammation of bronchial mucosa. Although the pathogenesis of the disease could not be clarified by a careful search of special staining and culturing for the infective agent, it was most suggestive of non-specific inflammation with a granulomatous response to some sort of inhaled agents.
...
PMID:Idiopathic granulomatous bronchitis. An unusual form of known granulomatous lung diseases or an unknown disease? 134 46
Prostaglandins (PG) have been suggested to play a role in the genesis of
cough
induced by angiotensin-converting enzyme inhibitors (ACE-I) and that inhibition of PG synthesis can reduce or abolish the incidence of this side effect. Moreover, experimental and clinical data suggest that nifedipine, a dihydropyridine Ca antagonist, can inhibit PG synthesis. Therefore, we wished to determine whether nifedipine can reduce
cough
induced by
ACE
-I as compared with indomethacin, a known inhibitor of PG synthesis. Fourteen hypertensive patients who developed
cough
during captopril chronic therapy randomly received slow-release nifedipine 20 mg twice daily (b.i.d.), indomethacin 50 mg b.i.d., and placebo b.i.d. for 1 week in a double-blind, cross-over design. At the end of each treatment phase,
cough
was evaluated by a self-administered questionnaire containing an ordinal scale for daily
cough
intensity and frequency. Indomethacin abolished or markedly reduced
cough
induced by
ACE
-I, whereas nifedipine reduced it but to a lesser degree. These findings suggest that PG can play a role in
cough
caused by
ACE
-I, and a dihydropyridine Ca antagonist can reduce the occurrence of this side effect.
...
PMID:Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. 138 63
The files of 172 consecutive hypertensive patients who received captopril or enalapril have been reviewed and the patients questioned on the development of chronic dry
cough
, persisting for at least two months. Forty patients had
cough
that was attributed to the drugs. Thirteen of them discontinued the drugs because of this adverse effect. In 15 of the 27 patients (55%) who continued receiving
ACE
inhibitors (7 males, 8 females, aged 65.4 +/- 9.9 years) the
cough
had spontaneously disappeared after 3.9 +/- 1.9 months of continued unaltered administration of these drugs and without any treatment aimed against this symptom. All patients were followed for at least four months after disappearance of
cough
, without recurrences. This finding may discourage withdrawal of
ACE
inhibitors from many patients who develop
cough
. Continuation of
ACE
inhibitors for at least several months, despite
cough
, (if the
cough
is not too severe) is probably justifiable.
...
PMID:Complete spontaneous remission of cough induced by ACE inhibitors during chronic therapy in hypertensive patients. 143 68
Two randomised, double-blind, cross-over studies in healthy volunteers given captopril 50 mg b.d. (n = 37; Study I) or enalapril 20 mg o.d. (n = 40; Study 2) and placebo for 2 weeks have been done to examine general well-being. Subjective experiences were evaluated using the standardised, Minor Symptoms Evaluation-profile (MSEP), which was completed during Run-in and on Days 1, 4, 7 and 14 in the morning. In comparison to placebo and the Run-in period, neither captopril nor enalapril affected the MSEP dimensions of Vitality, Contentment and Sleep. Captopril treatment was also assessed by applying the Quality of Life Clinical Questionnaire during Run-in and on Days 7 and 14. No improvement in the quality of life was demonstrated during treatment in comparison with the placebo or the Run-in period. Thus, no mood elevating effect of the
ACE
-inhibitors captopril and enalapril was demonstrated in healthy volunteers.
Cough
, which is believed to be a common adverse effect of
ACE
-inhibitors, was no more frequent during the treatment with captopril or enalapril than with placebo. It is concluded, that short-term treatment with captopril or enalapril is not perceived differently by healthy volunteers than placebo or no treatment at all. Furthermore, the
cough
associated with
ACE
-inhibition may be dependent on the duration of treatment, and two weeks was apparently too short for it to emerge.
...
PMID:General well-being during treatment with different ACE-inhibitors: two double-blind placebo-controlled cross-over studies in healthy volunteers. 145 16
Cough
induced by
ACE
-inhibitors may be related to bronchial hyperreactivity and/or to an accumulation of kinins. In a placebo-controlled, double-blind randomized study in asthmatic and hypertensive patients lung function and bronchial reactivity to histamine and bradykinin remained unaltered although in hypertensive patients with
cough
, reactivity to histamine tended to be more pronounced and bronchial hyperreactivity to be more frequent than in those without
cough
. The findings do not support a major role of kinins in
ACE
inhibitor-induced
cough
.
...
PMID:Cough induced by ACE-inhibitors. A kinin related phenomenon? 146 82
Dry cough is one of the most common side-effects of angiotensin converting enzyme inhibitors. The mechanism of
cough
induced by
ACE
inhibitors is not completely understood and may be related to bronchial hyperreactivity and/or an accumulation of kinins. In a placebo-controlled, double-blind randomised study, the effect of captopril on lung function and bronchial reactivity to histamine and bradykinin was investigated in eight asthmatic and 12 hypertensive patients (six with and six without
cough
during previous
ACE
inhibition). Lung function did not change in any patient after a single (25 mg) or short-term (2 x 25 mg for two weeks) administration of captopril. Bronchial reactivity to histamine and bradykinin remained unaltered in all groups. In hypertensive patients with
cough
, reactivity to histamine tended to be more pronounced and bronchial hyperreactivity to be more frequent than in those without
cough
. In conclusion, the present results do not support a major role for kinins in
cough
induced by
ACE
inhibition. On the other hand, bronchial hyperreactivity may be important in some patients. Additionally, these results demonstrate that treatment with
ACE
inhibitors is safe in most patients with bronchial asthma.
...
PMID:Airway responsiveness and cough induced by angiotensin converting enzyme inhibition. 146 96
Chronic cough may be the sole presenting manifestation of bronchial asthma (reference 3; Corrao et al, 1979), and "cough variant asthma (CVA)" has been used to categorize such patients. In order to clarify the clinical picture of CVA, we evaluated the clinical history, laboratory data, sputum cytology and pulmonary function in 14 subjects (5 males and 9 females, aged 14 to 65 years) compatible with the following diagnostic criteria: (1) chronic cough persistent for more than 8 weeks, (2) no wheeze nor dyspnea, (3) no rales, (4) no past history of asthma, (5) bronchial hyperreactivity to methacholine proven by Takishima's method (reference 13), (6) effectiveness of bronchodilators against
cough
, (7) normal chest X-ray film, (8) afebrile and negative CRP, (9) absence of sinusitis and postnasal drip, or if present, they are proved not to be responsible for the
cough
, and (10) no other causes of
cough
such as heart disease, prescription of
ACE
inhibitors, current smoking. The results were as follows. 1) Many of the subjects were atopic, with positive skin tests to one or more common allergens in 10 subjects, elevated serum IgE in 4 subjects, and past history and family history of atopy in 4 and 7 subjects, respectively. 2) Respiratory infection preceded the onset of CVA in 3 subjects. 3)
Cough
was generally nocturnal, but 2 subjects coughed only in the daytime. 4) FEV1.0% was decreased (less than 70%) in only 2 subjects, whereas V25 was decreased (less than 80% of predicted value) in 11 out of 12 evaluable subjects, which suggested peripheral airway obstruction.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Clinical study on cough variant asthma]. 150 83
Twenty-one subjects with known bronchial hyperreactivity were prospectively randomized in double-blind fashion to receive one of two angiotensin-converting enzyme inhibitors (ACE-I), enalapril or spirapril, for three weeks. Spirometry and methacholine provocation were performed prior to, during, and following
ACE
-I usage. Three of 21 subjects developed a nonproductive
cough
. However, only one subject wheezed slightly. Spirometry and bronchial reactivity (PD20) were unchanged throughout the study.
...
PMID:Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma. 155 63
The efficacy and safety of the treatment of arterial hypertension with the
ACE
-inhibitor quinapril, were evaluated in a multicentre study conducted in Italy. The study, lasting 14 weeks, after a preliminary wash-out period, allowed response-based titration of quinapril dose from 10 mg to 40 mg once a day, with provision to combine additional hydrochlorothiazide (12.5 to 25 mg), in case of persistently high diastolic pressure levels. The efficacy sample included 1267 patients: at therapy week 14, 78.6% of patients were treated with quinapril alone. Global response rate (intent-to-treat) was 83.3%, with a mean reduction of diastolic pressure of 15.8 mmHg (95% confidence interval from 15.5 to 16.2 mmHg). 91 patients reported 126 associated adverse events (7.0%); the most frequently reported event was
cough
(2.7%). First-dose hypotension was rarely reported (1.3%), even in elderly and diabetic patients.
...
PMID:[The Study Group of Quinapril in Arterial Hypertension. The Steering Committee]. 163 Jun 80
1
2
3
4
5
6
7
8
9
10
Next >>